CD8A and neoplasm: Combination strategies integrating TKIs with immunotherapy (e.g., lenvatinib or regorafenib with PD-1 blockade) have demonstrated synergistic immune activation through a reduction in tumor-associated macrophages and increased CD8+ T-cell infiltration in preclinical and translational studies [120,121].